知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

23 records (took 0.057 seconds)

筛选除外

    ANTI-C5a RECEPTOR ANTIBODIES
    1.
    发明申请
    ANTI-C5a RECEPTOR ANTIBODIES 审中-公开

    公开(公告)号：US20200017599A1

    公开(公告)日：2020-01-16

    申请号：US16443736

    申请日：2019-06-17

    Applicant: Novo Nordisk A/S

    Inventor： Kristian Kjaergaard ,  Soeren Lund ,  Stefan Zahn ,  Louise H. Zeuthen ,  Anker J. Hansen

    IPC: C07K16/28

    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

    KIR-Binding Agents and Methods of Use Thereof
    2.
    发明申请
    KIR-Binding Agents and Methods of Use Thereof 有权
    KIR结合剂及其使用方法

    公开(公告)号：US20130143269A1

    公开(公告)日：2013-06-06

    申请号：US13745081

    申请日：2013-01-18

    Applicant: Novo-Nordisk A/S - Novo Allé ,  Innate Pharma S.A.S

    Inventor： Søren Berg Padkaer ,  Peter Andreas, Nicolai, Reumert Wagtmann ,  Pieter Spee ,  Stefan Zahn ,  Kristian Kjaergaard ,  Anders Svensson

    IPC: C07K16/28

    CPC classification number: C07K16/2803 ,  C07K16/28 ,  C07K2299/00 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76

    Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.

    Abstract translation: 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负向信号可涉及KIR分子的配体结合诱导的构象重新取向，允许在特定结构域中的相邻KIR之间形成相互作用，从而导致 加速聚类。 提供了诸如单克隆抗体的方法和试剂，用于减少KIR介导的NK细胞细胞毒性的抑制，而不通过例如还原或阻断KIR的二聚化来降低或阻断HLA结合。

    THERAPEUTIC ANTIBODIES
    9.
    发明申请
    THERAPEUTIC ANTIBODIES 有权

    公开(公告)号：US20210238300A1

    公开(公告)日：2021-08-05

    申请号：US17127688

    申请日：2020-12-18

    Applicant: Novo Nordisk A/S

    Inventor： Kristian Kjaergaard ,  Soeren Lund ,  Stefan Zahn ,  Louise H. Zeuthen ,  Anker J. Hansen

    IPC: C07K16/28

    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.

Patent Agency Ranking